In-vitro and in-vivo activity of roxithromycin against Chlamydia trachomatis.
The object of study was the evaluation of both the in-vitro and in-vivo activity of roxithromycin against Chlamydia trachomatis. In-vitro activity against C. trachomatis was achieved by means of minimum inhibitory concentration (MIC) determinations and was recorded as 0.05 mg/l. In vivo activity was tested in 15 of 60 women, attending the Planning Clinic, who were positive for C. trachomatis. Microbiological diagnosis of chlamydial infection was achieved by using a monoclonal direct smear test (Biomerieux-C trachomatis direct IF). All the patients and their partners were treated with 150 mg of roxithromycin twice a day for 15 days. All the patients were requested to avoid unprotected sexual intercourse up to the end of the therapy. The criterion for clinical efficacy was defined as disappearance of clinical signs and the criterion for microbiological efficacy was evidence of eradication of C. trachomatis at the follow-up (mean time: 30 days). A clinical cure and chlamydial eradication was recorded for all the patients at the end of the treatment and at follow-up. Clinical safety was also satisfactory.
Furneri
P M
PM
Institute of Microbiology, University of Catania, Italy.
Sardo
S
S
Cianci
A
A
Palumbo
G
G
Tempera
G
G
D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002690:Chlamydia Infections / Q000188:drug therapy*; D002692:Chlamydia trachomatis / Q000187:drug effects* / Q000472:pathogenicity; D005260:Female; D006801:Humans; D015575:Roxithromycin / Q000494:pharmacology*; D012749:Sexually Transmitted Diseases; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D015575:Roxithromycin